Get the Stockscreener App
0.5962
11.44%
0.0612
After Hours:
.58
-0.0162
-2.72%
Xilio Therapeutics Inc stock is traded at $0.5962, with a volume of 1.78M.
It is up +11.44% in the last 24 hours and down -10.55% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.535
Open:
$0.56
24h Volume:
1.78M
Relative Volume:
3.35
Market Cap:
$40.27M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2014
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+14.68%
1M Performance:
-10.55%
6M Performance:
-14.83%
1Y Performance:
-59.72%
1-Day Range:
$0.5201
$0.6058
1-Week Range:
$0.503
$0.6058
52-Week Range:
$0.503
$1.49
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.5962 | 36.13M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing - TipRanks
Xilio Therapeutics Signs Underwriting Agreement With Leerink Partners - TradingView
Xilio Therapeutics Launches Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Prices Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics announces pricing of underwritten offering - marketscreener.com
Xilio Therapeutics Announces Pricing of Underwritten Offering - Bitget
Xilio Therapeutics Announces Pricing of $40 Million Underwritten Offering of Pre-Funded Warrants - Quiver Quantitative
Cancer drug developer Xilio raises $40M in warrant deal - Stock Titan
Xilio Therapeutics (NASDAQ:XLO) Shares Up 0.9% – Still a Buy? - Defense World
Earnings Risk: Can Xilio Therapeutics Inc deliver alphaM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn
Aug PostEarnings: Can Xilio Therapeutics Inc deliver alphaWeekly Investment Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Growth Recap: How cyclical is Xilio Therapeutics Incs revenue streamCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Sell Signal: What is AAMUs market position2025 Dividend Review & High Win Rate Trade Tips - baoquankhu1.vn
Highs Report: What is Espey Mfg Electronics Corps market positionJuly 2025 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
US Stocks Recap: Whats the fair value of Xilio Therapeutics Inc stockShort Setup & Technical Pattern Alert System - baoquankhu1.vn
Xilio Therapeutics (NASDAQ: XLO) reverse split vote to keep listing - Stock Titan
Performance Recap: Is Xilio Therapeutics Inc in accumulation or distribution phase2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Update Recap: Can Xilio Therapeutics Inc sustain earnings growthJuly 2025 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - Sahm
What dividend safety score for Xilio Therapeutics Inc. stockPortfolio Update Report & Technical Pattern Based Signals - Улправда
How Xilio Therapeutics Inc. stock reacts to bond yieldsWeekly Investment Summary & Weekly High Return Forecasts - Улправда
Is Xilio Therapeutics Inc. stock a contrarian buyEarnings Summary Report & Weekly Sector Rotation Insights - Улправда
Xilio Therapeutics secures $35.8 million from warrant exercises By Investing.com - Investing.com India
Xilio Therapeutics, Inc. Announces Change of Chair of the Board of Directors - MarketScreener
Why Xilio Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Summary & Breakout Confirmation Alerts - ulpravda.ru
Xilio Therapeutics extends cash runway into 2027 - MSN
Xilio Therapeutics Inc appoints Sara Bonstein as chair of board - MarketScreener
Xilio Therapeutics Announces Leadership Transition and Pipeline Updates - TipRanks
Xilio Therapeutics Announces Board Leadership Change - TradingView — Track All Markets
Is Xilio Therapeutics Inc. stock supported by strong fundamentalsMarket Risk Analysis & Safe Entry Point Alerts - Улправда
Xilio Therapeutics secures $35.8 million from warrant exercises - Investing.com
Xilio Therapeutics (NASDAQ: XLO) updates cash and appoints new board chair - Stock Titan
Xilio Therapeutics Extends Cash Runway Into 2027 - The Globe and Mail
Xilio shares soar on AbbVie collaboration deal - MSN
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises By Investing.com - Investing.com South Africa
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises - Investing.com Nigeria
Xilio Therapeutics Series B and C Warrants Update - TradingView — Track All Markets
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest - Defense World
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next? - Defense World
Xilio Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Will Xilio Therapeutics Inc. stock reach all time highs in 20252025 Market Overview & High Accuracy Swing Trade Signals - bolumsonucanavari.com
Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 PreEarnings & Risk Managed Investment Strategies - Улправда
Is Xilio Therapeutics Inc. stock dividend yield sustainableWeekly Market Report & High Conviction Investment Ideas - Улправда
Is Xilio Therapeutics Inc. stock a defensive play in 2025July 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Why Xilio Therapeutics Inc. stock remains undervaluedJuly 2025 Reactions & High Win Rate Trade Tips - bolumsonucanavari.com
Xilio Therapeutics Inc (XLO) looking to reclaim success with recent performance - setenews.com
Xilio Therapeutics Inc (XLO) can make a big difference with a little luck - setenews.com
Xilio Therapeutics, Inc. (XLO) -5.65% in After-hours: Slide Amid Routine Trading Conditions - Stocks Telegraph
Is Xilio Therapeutics Inc. stock trading at a premium valuationJuly 2025 Sentiment & Fast Gain Swing Alerts - Newser
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):